Skip to main content

Table 2 IDC molecular subtype analysis relative to FRA staining – TMA data

From: Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease

Variable

FRA positive

FRA negative

Total

P valuea

 

N (%)

N (%)

  

Marker

    

  ER/PR(+)

4 (14%)

24 (86%)

28

 

  ER/PR(-)

14 (45%)

17 (55%)

31

0.012

  Her2(+)

2 (15%)

11 (85%)

13

 

  Her2(-)

16 (35%)

30 (65%)

46

0.307

  ER/PR/Her2(-)

12 (67%)

6 (33%)

18

<0.0001

    

[ER/PR(+) or Her2(+) vs ER/PR/Her2(-)]

TNM Classification

    

  T1

3 (43%)

4 (57%)

7

 

  T2

10 (26%)

29 (74%)

39

 

  T3

5 (63%)

3 (37%)

8

 

  T4

0 (0%)

5 (100%)

5

 

Nodal Status

    

  N0

18 (35%)

33 (65%)

51

 

  N1/N2b

0 (0%)

8 (100%)

8

0.092

Tumor Grade

    

  Grade 1

1 (14%)

6 (86%)

7

 

  Grade 2

12 (36%)

21 (64%)

33

0.393

  Grade 3

5 (26%)

14 (74%)

19

0.6465c

  1. IDC invasive ductal carcinoma, TMA tissue microarray, FRA folate receptor alpha, ER estrogen receptor, PR progesterone receptor, Her2 human epidermal growth factor receptor type 2, TNM tumor node metastasis.
  2. a P values calculated via 2X2 contingency table analysis using Fisher’s exact test.
  3. b 4/8 (50%) of N1/N2 samples were Her2(+).
  4. c Grade 1 vs Grade 3.